Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal CancerThierry André, Sara Lonardi, María Luisa Limón et al.|New England Journal of Medicine|2024Cited by 208
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckKevin J. Harrington, Robert I. Haddad, Robert L. Ferris et al.|JAMA Oncology|2023Cited by 73
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine TumoursÉric Raymond, Nicola Fazio, Matthew H. Kulke et al.|Neuroendocrinology|2018Cited by 55
Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203).Michele Maio, Tibor Csőszi, Michael Schenker et al.|Journal of Clinical Oncology|2021Cited by 7